首页> 外文期刊>Bioorganic and Medicinal Chemistry Letters >Design and synthesis of trivalent ligands targeting opioid, cholecystokinin, and melanocortin receptors for the treatment of pain.
【24h】

Design and synthesis of trivalent ligands targeting opioid, cholecystokinin, and melanocortin receptors for the treatment of pain.

机译:设计和合成针对阿片类药物,胆囊收缩素和黑皮质素受体的三价配体,用于治疗疼痛。

获取原文
获取原文并翻译 | 示例
           

摘要

It has been known that co-administration of morphine with either cholecystokinin (CCK) receptor or melanocortin (MC) receptor antagonists enhance morphine's analgesic efficacy by reducing serious side effects such as tolerance and addiction. Considering these synergistic effects, we have designed trivalent ligands in which all three different pharmacophores for opioid, CCK, and MC receptors are combined in such a way as to conserve their own topographical pharmacophore structures. These ligands, excluding the cyclic compound, were synthesized by solid phase synthesis using Rink-amide resin under microwave assistance in very high yields. These trivalent ligands bind to their respective receptors well demonstrating that the topographical pharmacophore structures for the three receptors were retained for receptor binding. Ligand 10 was a lead compound to show the best biological activities at all three receptors.
机译:已知吗啡与胆囊收缩素(CCK)受体或黑皮质素(MC)受体拮抗剂的共同给药可通过降低严重的副作用(例如耐受性和成瘾性)来增强吗啡的镇痛效果。考虑到这些协同效应,我们设计了三价配体,其中以阿片样物质,CCK和MC受体的所有三种不同药效团的组合方式保存了它们自己的拓扑药效团结构。除环状化合物外,这些配体是在微波辅助下使用Rink-酰胺树脂通过固相合成以非常高的产率合成的。这些三价配体很好地结合到它们各自的受体上,表明保留了这三种受体的地形药效基团结构用于受体结合。配体10是在所有三种受体上均表现出最佳生物活性的先导化合物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号